Actavis PLC $200.96

down -2.55


24/4/2014 10:02 AM  |  NYSE : ACT  
Industries : Drugs / Drugs - Generic
Get Trend Analysis Icon Get ACT Trend Analysis - it has outperformed the S&P 500 by 87%

Partner Headlines

  1. Actavis Announces Celebrex Patent Challenge Settlement

    Benzinga
  2. IBD 50: Auto, Other IBD 50 Stocks Forming Bases

    IBD
  3. Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 5 ...

    Benzinga
  4. Actavis to Acquire Four Products from Akorn; Terms Undisclosed

    Benzinga
  5. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  6. Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage

    Benzinga
  7. Benzinga's Top Initiations

    Benzinga
  8. Corporate Cash Kings Escape U.S. Taxes

    FoxBusiness
  9. Facebook, Arris, Grifols Initiate New Bases

    IBD
  10. Market Wrap For April 9: Investors Breathe Sigh Of Relief Over Rate Worries

    Benzinga
  11. Stocks Add To Gains; Intuitive Surgical Slumps On Warning

    IBD
  12. Alexion, Biogen Among Leading Big-Cap Biotechs

    IBD
  13. Stocks Higher In Late Afternoon; First Solar Jumps

    IBD
  14. Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump

    IBD
  15. Meda Rejects Mylan's Bid

    IBD
  16. Caesarstone, Other Leading Stocks Showing Supporting Action

    IBD
  17. Mylan Bid Gets Rejected, But Generic-Drugmaker Rises

    IBD
  18. Mylan Rejected In Bid To Acquire Sweden's Meda

    IBD
  19. Four Top World Stocks Offer Follow-On Buy Points

    IBD
  20. Actavis

    IBD
  21. Actavis Completes Divestiture of Commercial Operations in Seven Western ...

    Benzinga
  22. Dow Chemical Benefits From 'Flight to Quality' Trade

    IBD
  23. Big Deals Drive Investment Banks, Brokers, Near Highs

    IBD
  24. Stocks On Pace To End Two-Session Slump

    IBD
  25. Selling Pressure Builds In Leading Growth Stocks, Nasdaq

    IBD
  26. Is A Weak-Volume Rebound A No-Go Buy Opportunity?

    IBD
  27. Biotechs, Medicals Get Hurt Amid Price-Inquiry News

    IBD
  28. Gentherm, Kors Setting Up in Tight Formations

    IBD
  29. Horizon Buys Ireland's Vidara

    IBD
  30. Actavis Announces Daytrana Patent Challenge Settlement

    Benzinga
  31. Horizon Pharma To Buy Vidara, Join Exodus To Ireland

    IBD
  32. Should You Buy Actavis?

    GuruFocus
  33. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  34. Market Wrap For March 13: Bears Come Out Of Hibernation As Dow Suffers ...

    Benzinga
  35. Stocks Down 1% In Late Afternoon As Volume Picks Up

    IBD
  36. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  37. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  38. How To Invest: Seek Stock Ideas In Sector Leaders

    IBD
  39. Stock Indexes Reverse Lower, But McDonald's Leaps 3%

    IBD
  40. Highflying Drug, Biotech Stocks Take Rare Drubbing

    IBD
  41. Major Indexes Give Up Early Gains; Jazz, 58.com Rise

    IBD
  42. US Stock Futures Edge Higher; All Eyes On Jobs Report

    Benzinga
  43. Stock Market Closes Mixed; Ambarella Tops Expectations

    IBD
  44. Stock Market Closes Mixed; Medical Leaders Drop

    IBD
  45. Precious Metals, Health Care Led Mutual Funds In Feb.

    IBD
  46. Top Mutual Funds Add To Health Care, Leisure And Banks

    IBD
  47. Drugmakers Actavis, Biogen, Valeant Hold Near Highs

    IBD
  48. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  49. Valeant Beats Q4 Estimates, Talks Buyout Strategy

    IBD
  50. Revenue Growth: Focus On Healthcare Stocks

    YCharts
Trading Center